International Urology and Nephrology

, 41:119

Renal effects of dual renin–angiotensin–aldosterone system blockade in patients with diabetic nephropathy

Authors

    • Cittadella General Hospital
  • N. Simioni
    • Cittadella General Hospital
  • A. Masiero
    • Department of Internal MedicineUniversity of Padova
Nephrology - Review

DOI: 10.1007/s11255-008-9490-0

Cite this article as:
Dalla Vestra, M., Simioni, N. & Masiero, A. Int Urol Nephrol (2009) 41: 119. doi:10.1007/s11255-008-9490-0

Abstract

Evidence from recent studies indicates that in patients with diabetic nephropathy combined therapy with ACE inhibitors (ACEI) and AT1-receptor antagonists (ARB) results in more complete blockade of the renin–angiotensin–aldosterone system (RAS) than monotherapy, and reduces proteinuria. Most of these trials, however, had short follow-up, included a small number of patients, and were heterogeneous, so the opportunity to start this treatment in these patients remains unclear. This review summarizes the results of these studies, describing the renal effects of dual RAS blockade in both type 1 and type 2 diabetic patients.

Keywords

ACE inhibitors AT1-receptor antagonists Diabetic nephropathy Renin–angiotensin–aldosterone system Type 1 diabetes Type 2 diabetes

Copyright information

© Springer Science+Business Media, B.V. 2008